Healios K.K. (HLOSF)
USD 1.35
(0.0%)
USD 1.35
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.28 Billion JPY | 13801.0% |
| 2022 | 81.19 Million JPY | -39.01% |
| 2021 | 133.13 Million JPY | -10.28% |
| 2020 | 148.38 Million JPY | 21.7% |
| 2019 | 121.92 Million JPY | -97.09% |
| 2018 | 4.19 Billion JPY | 18.77% |
| 2017 | 3.53 Billion JPY | 11.07% |
| 2016 | 3.18 Billion JPY | 34361.04% |
| 2015 | 9.22 Million JPY | -98.18% |
| 2014 | 507.11 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 14.54 Billion JPY | 13.93% |
| 2024 Q1 | 84.35 Million JPY | 13.13% |
| 2023 Q1 | 85.24 Million USD | 4.99% |
| 2023 FY | 11.28 Billion JPY | 13801.0% |
| 2023 Q3 | 82.65 Million USD | 4.35% |
| 2023 Q4 | 79.98 Million USD | -3.23% |
| 2023 Q2 | 79.2 Million USD | -7.08% |
| 2022 Q3 | 71.29 Million JPY | -40.59% |
| 2022 FY | 81.19 Million JPY | -39.01% |
| 2022 Q4 | 81.19 Million JPY | 13.89% |
| 2022 Q1 | 15.7 Billion JPY | 2.49% |
| 2022 Q2 | 119.99 Million JPY | -99.24% |
| 2021 Q1 | 136.19 Million JPY | -99.11% |
| 2021 FY | 133.13 Million JPY | -10.28% |
| 2021 Q4 | 15.32 Billion JPY | -1.16% |
| 2021 Q3 | 15.5 Billion JPY | 11768.17% |
| 2021 Q2 | 130.66 Million JPY | -4.07% |
| 2020 FY | 148.38 Million JPY | 21.7% |
| 2020 Q1 | 15.17 Billion JPY | 14.53% |
| 2020 Q2 | 14.65 Billion JPY | -3.41% |
| 2020 Q3 | 14.57 Billion JPY | -0.55% |
| 2020 Q4 | 15.32 Billion JPY | 5.09% |
| 2019 Q1 | 3.57 Billion JPY | -31.7% |
| 2019 Q4 | 13.25 Billion JPY | 9.3% |
| 2019 Q3 | 12.12 Billion JPY | 269.04% |
| 2019 Q2 | 3.28 Billion JPY | -8.14% |
| 2019 FY | 121.92 Million JPY | -97.09% |
| 2018 FY | 4.19 Billion JPY | 18.77% |
| 2018 Q4 | 5.23 Billion JPY | 5.82% |
| 2018 Q2 | 5.3 Billion JPY | 67.95% |
| 2018 Q3 | 4.94 Billion JPY | -6.71% |
| 2018 Q1 | 3.15 Billion JPY | -10.61% |
| 2017 Q3 | 3.75 Billion JPY | 5.58% |
| 2017 FY | 3.53 Billion JPY | 11.07% |
| 2017 Q1 | 3.04 Billion JPY | -4.31% |
| 2017 Q2 | 3.55 Billion JPY | 16.83% |
| 2017 Q4 | 3.53 Billion JPY | -5.9% |
| 2016 FY | 3.18 Billion JPY | 34361.04% |
| 2016 Q4 | 3.18 Billion JPY | -9.25% |
| 2016 Q3 | 3.5 Billion JPY | -4.33% |
| 2016 Q2 | 3.66 Billion JPY | 7.37% |
| 2016 Q1 | 3.41 Billion JPY | 207.3% |
| 2015 FY | 9.22 Million JPY | -98.18% |
| 2015 Q3 | 1.05 Billion JPY | -8.24% |
| 2015 Q2 | 1.14 Billion JPY | 0.0% |
| 2015 Q4 | 1.11 Billion JPY | 5.57% |
| 2014 FY | 507.11 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -21074.374% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -117693.51% |
| SQZ Biotechnologies Company | 50.03 Million USD | -22456.406% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -15474.506% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -19025.954% |
| Mesoblast Limited | 188.44 Million USD | -5889.558% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -292960.437% |
| Genus plc | 485 Million USD | -2227.216% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -193083.847% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -448450.427% |
| Marizyme, Inc. | 26.67 Million USD | -42211.899% |
| ContraFect Corporation | 32.53 Million USD | -34596.136% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -296926.316% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -569574.175% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -294780.825% |
| Intellipharmaceutics International Inc. | 12 Million USD | -93889.666% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -95729.624% |
| MultiCell Technologies, Inc. | 1617.67 USD | -697731823.075% |
| Accustem Sciences Inc. | 1.07 Million USD | -1045729.515% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -14479.485% |
| EV Biologics, Inc. | 2.11 Million USD | -533546.893% |
| Q BioMed Inc. | 8.13 Million USD | -138681.319% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -13509.453% |
| Neon Bloom, Inc. | 1.22 Million USD | -920376.296% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -219233.914% |
| Biomind Labs Inc. | 1.49 Million USD | -753063.594% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | -4524.436% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -61231.008% |
| Skye Bioscience, Inc. | 14.07 Million USD | -80107.62% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -561405.972% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -7943177.385% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -119138.265% |
| IMV Inc. | 37.93 Million USD | -29655.256% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -5612084.013% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -196338.42% |
| GB Sciences, Inc. | 5.41 Million USD | -208241.14% |
| Alpha Cognition Inc. | 7.16 Million USD | -157434.627% |
| HST Global, Inc. | 593.59 Thousand USD | -1901371.21% |
| CSL Limited | 18.62 Billion USD | 39.386% |
| Halberd Corporation | 728.71 Thousand USD | -1548782.354% |
| Enzolytics Inc. | 365.26 Million USD | -2990.051% |
| Resverlogix Corp. | 67.39 Million USD | -16647.285% |
| Affymax, Inc. | 8.87 Million USD | -127134.81% |
| SYBLEU INC | 681.41 Thousand USD | -1656311.017% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1345621.875% |
| argenx SE | 444.95 Million USD | -2436.684% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -14965.403% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -658418.086% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -94724.029% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -307853.478% |
| AVAX Technologies, Inc. | 3.99 Million USD | -282516.942% |
| Zenith Capital Corp. | 27.56 Thousand USD | -40940811.894% |
| Genscript Biotech Corporation | 1.32 Billion USD | -751.289% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -4729340.948% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -302151.61% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1657719.674% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -9407.066% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -124725.9% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -16864039.611% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -787075.326% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -22355.435% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -416142.416% |
| BioStem Technologies, Inc. | 15.9 Million USD | -70866.591% |
| ONE Bio Corp. | 27.49 Million USD | -40949.891% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2428784.073% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -41143777.811% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -896267.753% |
| Agentix Corp. | 2.51 Million USD | -449481.865% |
| LadRx Corporation | 2.2 Million USD | -512822.353% |
| Cell Source, Inc. | 15.8 Million USD | -71306.366% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -25252719.044% |
| Regen BioPharma, Inc. | 5.45 Million USD | -206711.912% |
| Regen BioPharma, Inc. | 5.45 Million USD | -206711.912% |
| NovAccess Global Inc. | 7.86 Million USD | -143487.137% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -45511.362% |
| Itoco Inc. | 1.65 Million USD | -682656.748% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -550065.362% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -186492.825% |
| Kadimastem Ltd | 3.5 Million USD | -321937.898% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2677285.38% |
| CytoDyn Inc. | 127.89 Million USD | -8725.277% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -27002938.35% |
| Mobile Lads Corp. | 1.31 Million USD | -859209.157% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -720480.039% |
| Qrons Inc. | 1.48 Million USD | -758071.656% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -102088.363% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1395434.586% |
| Rebus Holdings, Inc. | 5.24 Million USD | -215218.581% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -184875.02% |
| International Stem Cell Corporation | 5.27 Million USD | -213790.468% |
| Bioxytran, Inc. | 3.24 Million USD | -347245.745% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1803485.439% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -244359.485% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -27431.954% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -50593.914% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -557176.214% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -205942.351% |
| Neutra Corp. | 973.52 Thousand USD | -1159290.218% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -38800.569% |
| PureTech Health plc | 125.58 Million USD | -8887.681% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -300315.877% |
| IXICO plc | 1.9 Million USD | -593861.349% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -54880.759% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -10823.89% |
| CSL Limited | 18.62 Billion USD | 39.386% |
| Cellectis S.A. | 249.36 Million USD | -4426.217% |